The only S&P 500 company to top Tesla is Taser stun gun parent Axon Enterprise at 40%, while shares of multibillion-dollar ...

Jonathan Corrales, founder of Ready Aim Interview, helps tech job seekers rebuild confidence through coaching, and guiding ...

US stocks embarked on a major rally on Wednesday as traders took in Donald Trump's election win. Major indexes soared to fresh records, with the Dow Jones Industrial Average climbing more than ...

These stocks have all lost more than 80% of their value in the past five years. It can sometimes be dangerous to buy stocks and forget about them. While it may be a potentially good strategy for ...

There is no shortage of warnings to investors that stocks have become expensive. We are in the midst of a long bull market for stocks — if one looks past the significant pullbacks in 2022 and ...

Pfizer faces some problems, but has a brighter future than meets the eye. Yes, bargains can still be found in the stock market. How richly valued are stocks right now? Legendary investor Warren ...

Let's explore three sectors and six growth stocks that could deliver on your long-term wealth creation goals. For patient investors, long-term growth stocks have upside. First, long holding ...

Stop assuming you'll remember that one cool product you saw scrolling, and just save the link already. View Entire Post › ...

Here's how to turn 12 days of PTO into maximum vacation time in 2025. 2025 federal holidays that make long weekends There are 11 recognized federal holidays in 2025 that can easily be converted ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Choosing to invest in pure-play AI stocks involves selecting companies that prioritize artificial intelligence as their core business. These firms are typically expected to achieve growth rates ...

The stock has more than doubled in 2024 but is still trading under $5. Investors are growing increasingly optimistic that imetelstat could gain additional approvals. Geron is in phase 3 clinical ...